Djebbari, F., Rampotas, A., Vallance, G., Panitsas, F., Basker, N., Sangha, G., Salhan, B., Karim, F., Al‐Kaisi, F., Gudger, A., Ngu, L., Poynton, M., Lam, H. P. J., Morgan, L., Yang, L., Young, J., Walker, M., Tsagkaraki, I., Anderson, L., Chauhan, S. R., Maddams, R., Soutar, R., Triantafillou, M., Prideaux, S., Obeidalla, A., Eyre, T. A., Bygrave, C., Kothari, J., Basu, S., & Ramasamy, K. (2023). frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients. British journal of haematology, 201, 162–167. http://access.bl.uk/ark:/81055/vdc_100181747844.0x00005f